X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
female (8) 8
index medicus (8) 8
male (7) 7
humans (6) 6
middle aged (6) 6
aged (5) 5
clopidogrel (5) 5
abridged index medicus (4) 4
cerebral infarction (4) 4
heart attacks (4) 4
medicine, general & internal (4) 4
myocardial infarction (4) 4
myocardial-infarction (4) 4
platelet reactivity (4) 4
thrombosis (4) 4
acute coronary syndromes (3) 3
animals (3) 3
cardiovascular diseases (3) 3
clinical trials (3) 3
drug dosages (3) 3
endothelin (3) 3
hematology (3) 3
inhibition (3) 3
percutaneous coronary intervention (3) 3
platelet aggregation inhibitors - administration & dosage (3) 3
prasugrel (3) 3
risk (3) 3
stroke (3) 3
ticlopidine - administration & dosage (3) 3
ticlopidine - analogs & derivatives (3) 3
angina (2) 2
angina pectoris (2) 2
antibodies, monoclonal - adverse effects (2) 2
association (2) 2
bile duct obstruction (2) 2
bleeding (2) 2
blood platelets - drug effects (2) 2
cardiac & cardiovascular systems (2) 2
cardiovascular disease (2) 2
cardiovascular diseases - epidemiology (2) 2
cell biology (2) 2
cholesterol (2) 2
cirrhosis (2) 2
double-blind method (2) 2
drug therapy (2) 2
european union (2) 2
expression (2) 2
growth-factor-beta (2) 2
health risk assessment (2) 2
history (2) 2
hypertension (2) 2
liver - metabolism (2) 2
liver cirrhosis (2) 2
modulation (2) 2
myocardial infarction - drug therapy (2) 2
patients (2) 2
pcsk9 (2) 2
peripheral vascular disease (2) 2
platelet aggregation - drug effects (2) 2
platelet aggregation inhibitors - adverse effects (2) 2
platelet function tests (2) 2
platelet function tests - methods (2) 2
politics (2) 2
rats (2) 2
rats, wistar (2) 2
statin therapy (2) 2
stellate cells (2) 2
therapy (2) 2
ticlopidine - adverse effects (2) 2
transformation period (2) 2
1945 (1) 1
[sdv.mhep.csc]life sciences [q-bio]/human health and pathology/cardiology and cardiovascular system (1) 1
[sdv.mhep]life sciences [q-bio]/human health and pathology (1) 1
[sdv]life sciences [q-bio] (1) 1
academic research consortium (1) 1
actin (1) 1
actins - metabolism (1) 1
acute coronary syndrome (1) 1
acute coronary syndrome - blood (1) 1
acute coronary syndrome - complications (1) 1
acute coronary syndrome - drug therapy (1) 1
acute coronary syndrome - epidemiology (1) 1
acute coronary syndrome - therapy (1) 1
adapt-des (1) 1
adenosine diphosphate - metabolism (1) 1
adult (1) 1
aged, anti-inflammatory agents, antibodies, monoclonal, atherosclerosis, c-reactive protein, cardiovascular diseases, dose-response relationship, drug, double-blind method, female, humans, incidence, infection, interleukin-1beta, lipids, male, middle aged, myocardial infarction, neutropenia, secondary prevention, stroke (1) 1
aggregation (1) 1
analysis (1) 1
angioplasty (1) 1
angiotensin (1) 1
anti-inflammatory agents - administration & dosage (1) 1
anti-inflammatory agents - adverse effects (1) 1
antibodies, monoclonal - administration & dosage (1) 1
antibodies, monoclonal - therapeutic use (1) 1
anticholesteremic agents - adverse effects (1) 1
anticholesteremic agents - therapeutic use (1) 1
anticoagulants (1) 1
apolipoprotein b (1) 1
arachidonic acid - metabolism (1) 1
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


by Sibbing, Dirk and Aradi, Dániel and Aradi, Daniel and Jacobshagen, Claudius and Gross, Lisa and Trenk, Dietmar and Geisler, Tobias and Orban, Matthias and Orban, Martin and Hadamitzky, Martin and Merkely, Béla and Kiss, Róbert Gábor and Komócsi, András and Dézsi, Csaba A and Dézsi, Csaba András and Dézsi, András Döme and Holdt, Lesca and Felix, Stephan and Felix, Stephan B and Parma, Zofia and Parma, Radoslaw and Klopotowski, Mariusz and Schwinger, Robert and Schwinger, Robert H G and Rieber, Johannes and Huber, Kurt and Neumann, Franz-Josef and Koltowski, Lukasz and Mehilli, Julinda and Huczek, Zenon and Massberg, Steffen and Lesiak, Maciej and Komosa, Anna and Kowara, Michal and Rymuza, Bartosz and Malek, Lukasz and Veress, Gábor and Lux, Árpád and Papp, Judit and Kovács, Andrea and Amer, Sayour and Ruzsa, Zoltán and Róna, Szilárd and Ili, Renáta and Ungi, Imre and Nagy, Ferenc and Zweiker, Robert and Tóth-Gayor, Gábor and Haller, Paul and von Scheidt, Wolfgang and Blüthgen, Andreas and Leggewie, Stefan and Kreider-Stempfle, Hans Ulrich and Remp, Thomas and Kara, Kaffer and Mügge, Andreas and Wutzler, Alexander and Fichtlscherer, Stephan and Zeiher, Andreas M and Seeger, Florian and Hinterseer, Martin and König, Andreas and Lederle, Susanne and Czepluch, Frauke and Maier, Lars and Schillinger, Wolfgang and Sossalla, Samuel and Hummel, Astrid and Karakas, Mahir and Sydow, Karsten and Rudolph, Tanja and Halbach, Marcel and Gori, Tommaso and Münzel, Thomas and May, Andreas and Gerstenberg, Carsten-Manuel and Pilecky, David and Deichstetter, Markus and Kääb, Stefan and Löw, Anja and Sattler, Stefan and Deuschl, Sabine and Teupser, Daniel and Mudra, Harald and Räder, Thomas and Schütz, Torsten and Vahldiek, Felix and Divchev, Dimitar and Ince, Hüseyin and Nienaber, Christoph A and Radunski, Henning and Boekstegers, Peter and Horstkotte, Jan and Mueller, Ralf and Müller, Karin and Rasp, Oliver and TROPICAL-ACS Investigators
The Lancet, ISSN 0140-6736, 10/2017, Volume 390, Issue 10104, pp. 1747 - 1757
Current guidelines recommend potent platelet inhibition with prasugrel or ticagrelor for 12 months after an acute coronary syndrome managed with percutaneous... 
ELUTING STENTS | MEDICINE, GENERAL & INTERNAL | CLOPIDOGREL | THERAPY | TICAGRELOR | TREATMENT PATTERNS | ACADEMIC RESEARCH CONSORTIUM | PRASUGREL | DIPHOSPHATE RECEPTOR INHIBITOR | MYOCARDIAL-INFARCTION PATIENTS | PLATELET REACTIVITY | Myocardial Infarction - epidemiology | Acute Coronary Syndrome - epidemiology | Drug Administration Schedule | Hemorrhage - epidemiology | Humans | Middle Aged | Europe - epidemiology | Male | Prasugrel Hydrochloride - adverse effects | Ticlopidine - analogs & derivatives | Platelet Aggregation Inhibitors - administration & dosage | Platelet Function Tests | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Acute Coronary Syndrome - therapy | Clopidogrel | Female | Stroke - epidemiology | Hemorrhage - chemically induced | Prasugrel Hydrochloride - administration & dosage | Drug Monitoring | Percutaneous Coronary Intervention | Platelet Aggregation Inhibitors - adverse effects | Transluminal angioplasty | Care and treatment | Coronary heart disease | Cardiac patients | Analysis | Anticoagulants | Heart attacks | Blood platelets | Angioplasty | Clinical trials | Acute coronary syndromes | Drug therapy | Patients | Clinical outcomes | Myocardial infarction | Intervention | Medical services | Bleeding | Consortia | Randomization | Motivation | Inhibition | Cerebral infarction | Stroke | Test procedures | Health risks | Thrombosis | Coronary vessels | Biomarkers | Infarction | Cardiovascular diseases | Platelets
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 09/2017, Volume 377, Issue 12, pp. 1119 - 1131
Patients with myocardial infarction and a high-sensitivity CRP level of 2 mg or more per liter were assigned to one of three canakinumab doses or placebo. The... 
C-REACTIVE PROTEIN | MEDICINE, GENERAL & INTERNAL | HEART-DISEASE | MYOCARDIAL-INFARCTION | STATIN THERAPY | CLONAL HEMATOPOIESIS | INFLAMMATION | CARDIOVASCULAR-DISEASE | INTERLEUKIN-1-BETA INHIBITION | RISK | CORONARY-ARTERY-DISEASE | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Male | Secondary Prevention | Infection - etiology | Incidence | Dose-Response Relationship, Drug | Anti-Inflammatory Agents - adverse effects | C-Reactive Protein - metabolism | Lipids - blood | Cardiovascular Diseases - epidemiology | Cardiovascular Diseases - mortality | Anti-Inflammatory Agents - administration & dosage | Female | Neutropenia - chemically induced | Interleukin-1beta - antagonists & inhibitors | Stroke - prevention & control | Atherosclerosis - drug therapy | Double-Blind Method | Interleukin-1beta - immunology | Atherosclerosis - blood | Myocardial Infarction - drug therapy | Antibodies, Monoclonal - administration & dosage | Aged | Myocardial Infarction - prevention & control | Myocardial infarction | Cerebral infarction | Stroke | Heart attacks | C-reactive protein | Cytokines | Clinical trials | Cardiovascular disease | Innate immunity | Inflammation | Angina | Angina pectoris | Thrombosis | Cholesterol | Disease prevention | Proteins | Arteriosclerosis | Atherosclerosis | Cardiovascular diseases | Health risk assessment | Drug therapy | Drug dosages | Klinisk medicin | Clinical Medicine
Journal Article
Thrombosis and Haemostasis, ISSN 0340-6245, 10/2019, Volume 19, Issue 10, pp. 1606 - 1616
Abstract There are clinical scenarios where the balance between the risk of ischemic and bleeding events leads to the clinical decision to reverse the... 
Theme Issue Article
Journal Article
Heart, ISSN 1355-6037, 08/2013, Volume 99, Issue Suppl 3, pp. A160 - A160
Objectives A more rapid onset of antiplatelet effect following loading with prasugrel and ticagrelor compared to clopidogrel was demonstrated for healthy... 
Journal Article
Platelets, ISSN 0953-7104, 10/2016, Volume 27, Issue 7, pp. 668 - 672
Testing of P2Y 12 -receptor antagonist effects can support clinical decision-making. However, most platelet function assays use only ADP as agonist which is... 
Clopidogrel | platelet reactivity | prasugrel | prostaglandin E1
Journal Article